Clinical trial · Interventional
Pilot Study of Stomach Cancer Early Detection and Prevention With Endoscopy
Primary Objective: The Primary Objective of the Study is to Evaluate the Acceptability and Feasibility of EGD-SC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Screening esophagogastroduodenoscopy (EGD )provides three distinct opportunities to decrease gastric cancer (GC) morbidity and mortality. has potential to discover cancer in early stages before the onset of symptoms, leading to higher rates of survival. Second, premalignant lesions such as adenomatous polyps, intestinal metaplasia and dysplasia can be discovered and removed with local resection, akin to polypectomies during screening colonoscopies, preventing the development of cancer. Third, EGD discovery and treatment of active Helicobacter pylori (HP) infection of the stomach provides an opportunity for primary prevention of GC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| esophagogastroduodenoscopy (EGD) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EGD at time of routine screening colonoscopy
- description
- This happens on Day 0. Screening for EGD, biopsy samples from esophagus, stomach, gastrointestinal junction, and duodenum AE's.
- interventionNames
- Procedure: esophagogastroduodenoscopy (EGD)
Primary outcomes (1)
- measure
- Acceptability and feasibility of EGD-SC measured by Linear Scale
- timeFrame
- Pre-Study Screening Day -30 to day0
- description
- To achieve the goal of assessing feasibility of EDG-SC as well as estimates of effect size needed to determine sample size and power for the planned study, the investigator will collect data on the number of participants contacted, number eligible, and number who agree to EGD-SC.
Secondary outcomes (1)
- measure
- Number of participants with AE's will be measured by the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Have provided signed informed consent for the trial * Aged =40 and =80 years at the time of informed consent * Not planned to undergo EGD and not had EGD in the last five years * Planned to undergo colonoscopy * Half of the recruited subjects will be from high-risk groups * Willing and able to comply with all aspects of the protocol Exclusion Criteria: * Persons with total gastrectomy * Persons with anatomic alteration that precludes EGD * Medical conditions that substantially increase risks for EGD * Had EGD in the last five years
References
Publications (0)
Data not yet available